Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study - Concepedia

Concepedia

Publication | Open Access

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

DOI Full Paper Access

645

Citations

33

References

2008

Year

James C. Yao, Alexandria T. Phan, David Z. Chang, Robert A. Wolff, Kenneth R. Hess, Sanjay Gupta, Carmen Jacob, Jeannette E. Mares, Andrea Landgraf, Asif Rashid,

Journal of Clinical Oncology

Abstract

RAD001 at 5 or 10 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity. Confirmatory studies are ongoing.

References

	Year	Citations

Page 1